Register to view the archived recording here.
UT Southwestern Team Uncovers Role of miRNA in Slowing ALS Progression
Miragen Therapeutics, which holds the rights to the discovery, is interested in seeing the work advance. But a company official said that development of a miRNA-targeting drug for ALS would likely only occur in earnest with a partner.
New to GenomeWeb? Register here quickly.